Peptomyc S.L., a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients, announces the closure of a Series A financing of 4.2 million euros. The investment round was led by Alta Life Sciences Spain I FCR, and includes current investors HealthEquity and business angels, that had already participated in the seed round of 2016. RCD, a leading legal firm in the biotech sector, has advised on…
